- All
- Product Management
- News
- Introduction
- Enterprise outlets
- FAQ
- Enterprise Video
- Enterprise Atlas
Initial screening for prostate cancer
Common initial screening methods for prostate cancer include digital rectal examination (DRE), prostate-specific antigen (PSA) analysis, and transrectal ultrasound (TRUS).TRUSetc.
In initial prostate cancer screening, DRE is limited by the clinician's experience; PSA can easily lead to overtreatment of clinically unclear prostate cancer, and there is currently no consensus or treatment guidelines to use PSA as the top priority evidence for prostate cancer diagnosis; in contrast,TRUShas been further developed and widely used clinically. Currently, ultrasound-guided transrectal prostate biopsy is the gold standard for diagnosing prostate cancer, with ultrasound sensitivity for prostate cancer lesions reaching40～50%. However, relevant studies have shown that due to limitations such as smaller tumor volume, difficult lesion localization, and the experience of the clinician performing the procedure, its sensitivity and specificity in diagnosing prostate cancer are not high.
Previous Page
Previous Page